CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

CareDx (Nasdaq: CDNA) will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47^th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026.

About CareDx

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218713403/en/

Investor Relations
Caroline Corner
investor@caredx.com

Source: CareDx, Inc.

Key Terms

precision medicine medical

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.